Jordi Niubó

Jordi Niubó

Auto-generated profile, based on publicly available information

Jordi Niubó

Microbiology Department, Hospital Universitari Bellvitge, University of Barcelona-IDIBELL, L'Hospitalet de Llobregat, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Enfermedades Infecciosas y Microbiología Clínica
Verified
Journal Article
Closed access
MMMontserrat Muñoz-Sellart
Montserrat Muñoz-Sellart
CGCarolina Garcia-Vidal
Carolina Garcia-Vidal
SMSergio Martínez-Yelamos
Sergio Martínez-Yelamos
JNJordi Niubó
Jordi Niubó
PFPedro Fernández-Viladrich
Pedro Fernández-Viladrich

15 March 2022 in Vaccine
Verified
Journal Article
Closed access
JCJordi Càmara
Jordi Càmara
AGAida Gonzalez-Diaz
Aida Gonzalez-Diaz
IBIrene Barrabeig
Irene Barrabeig
MFMiguel Fernández-Huerta
Miguel Fernández-Huerta
LCLaura Calatayud
Laura Calatayud
ACArdanuy Carmen
Ardanuy Carmen

12 January 2021 in medRxiv
Verified
Preprint
Open access
PDF file
XSXavier Solanich
Xavier Solanich
AAA Antolí
A Antolí
NPN Padullés
N Padullés
MFMarta Fanlo-Maresma
Marta Fanlo-Maresma
AIA Iriarte
A Iriarte
XCXavier Corbella
Xavier Corbella
Introduction Some COVID-19 patients evolve to severe lung injury and systemic hyperinflammatory syndrome triggered by both the coronavirus infection and the subsequent host-immune response. Accordingly, the use of immunomodulatory agents has been suggested but still remains controversial. Our working hypothesis is that methylprednisolone pulses and tacrolimus may be an effective and safety drug combination for treating severe COVID-19 patients. Methods and analysis TACROVID is a randomized, open-label, single-center, phase II trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus plus standard of care (SoC) versus SoC alone, in patients at advanced stage of COVID-19 disease with lung injury and systemic hyperinflammatory response. Patients are randomly assigned (1:1) to one of two arms (42 patients in each group). The primary aim is to assess the time to clinical stability after initiating randomization. Clinical stability is defined as body temperature ≤ 37.5°C, and PaO2/FiO2 > 400 and/or SatO2/FiO2 > 300, and respiratory rate ≤24 rpm; for 48 consecutive hours. Discussion Methylprednisolone and tacrolimus might be beneficial to treat those COVID-19 patients progressing into severe pulmonary failure and systemic hyperinflammatory syndrome. The rationale for its use is the fast effect of methylprednisolone pulses and the ability of tacrolimus to inhibit both the CoV-2 replication and the secondary cytokine storm. Interestingly, both drugs are low-cost and can be manufactured on a large scale; thus, if effective and safe, a large number of patients could be treated in developed and developing countries. Trial registration number NCT04341038 / EudraCT: 2020-001445-39